UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 264

Sortiert nach

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

The lancet oncology, 2016-03, Vol.17 (3), p.299-308

2016

Link zum Volltext

Verfügbarkeit prüfen

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Nature medicine, 2019-11, Vol.25 (11), p.1715-1720

2019

Link zum Volltext

Verfügbarkeit prüfen

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Science (American Association for the Advancement of Science), 2018-02, Vol.359 (6375), p.582-587

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Science (American Association for the Advancement of Science), 2015-04, Vol.348 (6230), p.124-128

2015

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2980-2987

2016

Link zum Volltext

Verfügbarkeit prüfen

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

PloS one, 2020-09, Vol.15 (9), p.e0238358-e0238358

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2746-2758

2019

Link zum Volltext

Verfügbarkeit prüfen

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

The lancet oncology, 2015-03, Vol.16 (3), p.257-265

2015

Link zum Volltext

Verfügbarkeit prüfen

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Clinical cancer research, 2021-03, Vol.27 (6), p.1631-1640

2021

Link zum Volltext

Verfügbarkeit prüfen

PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

Cancer cytopathology, 2017-12, Vol.125 (12), p.896-907

2017

Link zum Volltext

Verfügbarkeit prüfen

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2018-07, Vol.6 (1), p.75-75, Article 75

2018

Link zum Volltext

Verfügbarkeit prüfen

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Clinical cancer research, 2007-09, Vol.13 (17), p.5150-5155

2007

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Link zum Volltext

Verfügbarkeit prüfen

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Cancer discovery, 2021-02, Vol.11 (2), p.282-292

2021

Link zum Volltext

Verfügbarkeit prüfen

Synchronous Pulmonary Adenocarcinomas

American journal of clinical pathology, 2020-06, Vol.154 (1), p.57-69

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

BMC cancer, 2018-02, Vol.18 (1), p.225-225, Article 225

2018

Link zum Volltext

Verfügbarkeit prüfen

Combining chemotherapy with PD-1 blockade in NSCLC

Pharmacology & therapeutics (Oxford), 2018-06, Vol.186, p.130-137

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for immunotherapy of cancer, 2022-08, Vol.10 (8), p.e005147

2022

Link zum Volltext

Verfügbarkeit prüfen

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Journal for immunotherapy of cancer, 2023-07, Vol.11 (7), p.e007309

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1986-1988

2017

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e005471

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.481-485

2011

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of clinical oncology, 2019-10, Vol.37 (28), p.2518-2527

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-02, Vol.26 (4), p.639-643

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 264

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(255)

Publikationsform

Artikel
(264)

Sprache

Englisch
(263)
Japanisch
(32)

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(125)
Oncology
(111)
Humans
(109)
Female
(78)
Male
(76)
Middle Aged
(73)
Aged
(72)
Lung Neoplasms - Drug Therapy
(63)
Adult
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(45)
Aged, 80 And Over
(43)
Immunotherapy
(42)
Biological And Medical Sciences
(39)
Lung Cancer
(39)
Medical Sciences
(39)
Tumors
(36)
Lung Neoplasms - Pathology
(35)
Treatment Outcome
(33)
Cancer
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Synchronous Pulmonary Adenocarcinomas

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Combining chemotherapy with PD-1 blockade in NSCLC

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

Suchergebnisse filtern